サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433660

北米の外用薬CDMOの市場規模、シェア、動向分析レポート：製品タイプ別、サービスタイプ別、スポンサー別、国別、セグメント別予測、2024年～2030年

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Product Type (Semi-Solid, Liquid), By Service Type (Contract Development, Contract Manufacturing), By Sponsors, By Country, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 125 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
北米の外用薬CDMOの市場規模、シェア、動向分析レポート：製品タイプ別、サービスタイプ別、スポンサー別、国別、セグメント別予測、2024年～2030年
出版日: 2024年01月31日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の外用薬CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、北米の外用薬CDMO市場規模は、2024年から2030年にかけて10.7%のCAGRを記録し、2030年までに264億5,000万米ドルに達すると予測されています。

研究開発活動への投資の増加と、いくつかの皮膚科疾患に対する新規治療薬へのニーズの高まりが、外用薬CDMO市場の需要拡大に寄与しています。投与が容易で副作用が最小限に抑えられることから、複数の外用液に対する消費者の嗜好が高まっていることも、市場の成長を支える要因となっています。

斬新なイノベーションと新製品開発に対するニーズの高まりが市場の需要を改善すると予想され、競争圧力と価格への懸念が新薬開発と製造のアウトソーシングを企業に促しています。これが市場全体の成長を促進すると予想されます。さらに、CDMOはナノテクノロジーなどの先端技術を活用して薬剤粒子を分子レベルで操作し、薬剤の安定性とバイオアベイラビリティを高めています。さらに、マイクロカプセル化技術は繊細な成分を保護し、放出制御と標的ドラッグデリバリーを可能にすることで、治療効果を高めています。このような技術の進歩は、北米における市場成長の可能性を加速させています。

CDMOは製薬企業との協力・提携に積極的に関与し、革新的な医薬品開発と複数の外用製剤の製造に関する長期契約を獲得しており、これが市場の需要を促進すると予想されます。例えば、2023年1月、皮膚外用剤に特化した著名なプロバイダーであるスイス系米国CDMOは、EveryDropディスペンシング・プラットフォームの発明者であるLiquiGlideと提携しました。この提携により、同社はLiquiGlideの革新的な無毒性の滑りやすい表面技術を利用し、液体と固体間の摩擦をなくし、消費者向けパッケージ商品の製品廃棄物をなくします。

北米の外用薬CDMO市場レポートハイライト：

  • 製品タイプ別では、半固形製剤分野が2023年の売上高シェア65.0%以上で市場を独占しています。これは、投与が容易であることや、いくつかの副作用のために経口投与経路と比較して患者が外用薬を好むことなど、多くの利点があるためであり、これが同分野の需要を促進すると予想されます。
  • サービスタイプ別では、受託製造部門が予測期間中に大幅なCAGRで成長する見込みです。
  • スポンサー別では、製薬会社が2023年に最大の市場シェアを占めています。革新的な外用薬を開発・商品化するための製薬企業による研究開発投資の開拓が、市場の収益成長を押し上げると予想されます。
  • 米国は北米の外用薬CDMO業界を支配していますが、これは同地域における市場参入企業の存在感の強さ、質の高いヘルスケアに対する政府の支援、化粧品に対する需要の高さといった要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 北米の外用薬CDMO市場変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 北米の外用薬CDMO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
  • 価格分析
  • 外用薬CDMO能力の見通し
  • 製品カテゴリー別の北米の外用薬CDMO市場見通し
  • COVID-19のパンデミックの影響

第4章 北米の外用薬CDMO市場：製品タイプの推定・動向分析

  • 製品タイプの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 北米の外用薬CDMO市場の製品別展望
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 北米の外用薬CDMO市場：サービスタイプの推定・動向分析

  • サービスタイプの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • サービスタイプ別の北米の外用薬CDMO市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 北米の外用薬CDMO市場：スポンサーの推定・動向分析

  • スポンサーの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • スポンサー別の北米の外用薬CDMO市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第7章 北米の外用薬CDMO市場：国の推定・動向分析

  • 国の市場シェア分析、2023年と2030年
  • 国の市場ダッシュボード
  • 国の市場スナップショット
  • 市場規模と予測動向分析、2018年から2030年まで
  • 米国
  • カナダ

第8章 競合情勢

  • 会社/競合の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレイヤー
    • 企業の市場シェア分析、2023年
  • 企業プロファイル
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre SA
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD.
    • MedPharm Ltd.
    • Zenvisionpharma
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Topical Drugs CDMO: Market Revenue Estimates and Forecast, 2018 - 2030 (USD Billion)
  • Table 4 Global Topical Drugs: Market Revenue Estimates and Forecast, 2018 - 2030 (USD Billion)
  • Table 5 Development Stages Baseline Model Parameter Estimates, By Topical Drugs
  • Table 6 Global Topical Drugs CDMO Manufacturing Container Capacity/Batch
  • Table 7 Global Topical Drugs Capacity, by Product Type (per unit)
  • Table 8 Global Topical Drugs Capacity, by Container Type (per unit)
  • Table 9 North America Topical Drugs CDMO Market Share, By Product Category, 2023 (%)
  • Table 10 List of Major Prescription Drugs, by Product Type (2022)
  • Table 11 List of Major Generic Drugs, by Product Type (2022)
  • Table 12 List of major OTC Drugs, by Product Type (2022)
  • Table 13 North America Topical Drugs CDMO market revenue estimates and forecast, by Product type, 2018 - 2030 (USD Million)
  • Table 14 North America Topical Drugs CDMO market revenue estimates and forecast, by Semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 15 North America Topical Drugs CDMO market revenue estimates and forecast, by Liquid formulations drugs, 2018 - 2030 (USD Million)
  • Table 16 North America Topical Drugs CDMO market revenue estimates and forecast, by service type, 2018 - 2030 (USD Million)
  • Table 17 North America Topical Drugs CDMO market revenue estimates and forecast, by contract development, 2018 - 2030 (USD Million)
  • Table 18 North America Topical Drugs CDMO market revenue estimates and forecast, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 19 North America Topical Drugs CDMO market revenue estimates and forecast, by sponsors, 2018 - 2030 (USD Million)
  • Table 20 North America Topical Drugs CDMO market revenue estimates and forecast, by country, 2018 - 2030 (USD Million)
  • Table 21 Company profiles: Company overview
  • Table 22 Company profiles: Financial performance
  • Table 23 Company profiles: Service benchmarking
  • Table 24 Key Company initiating service launches/upgrades
  • Table 25 Key companies initiating mergers/acquisitions/joint ventures
  • Table 26 Key companies initiating partnerships
  • Table 27 Key companies initiating expansion
  • Table 28 Key companies initiating others 

List of Figures

  • Fig. 1 North America topical drugs CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
  • Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
  • Fig. 14 North America topical drugs CDMO market dynamics
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
  • Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
  • Fig. 19 Semi-solid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Creams market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Ointments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Lotions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Liquid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Suspensions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Solutions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Solid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Transdermal products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
  • Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
  • Fig. 31 Contract development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Formulation development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Analytical testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Stability testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Clinical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Commercial market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
  • Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
  • Fig. 41 Pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
  • Fig. 45 Regional outlook, 2023 & 2030
  • Fig. 46 Regional Market Share Analysis, 2023 & 2030
  • Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Market participant categorization
  • Fig. 54 Heat map analysis 
目次
Product Code: GVR-4-68040-188-4

North America Topical Drugs CDMO Market Growth & Trends:

The North America topical drugs CDMO market size is anticipated to reach USD 26.45 billion by 2030, registering a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.

The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.

CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide's innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.

North America Topical Drugs CDMO Market Report Highlights:

  • Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 65.0% share in 2023, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
  • Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
  • Based on sponsors, the pharmaceutical companies segment held the largest market share in 2023. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
  • The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in the U.S.
    • 1.5.2. Data for primary interviews in Canada
  • 1.6. Information or Data Analysis
    • 1.6.1. Data analysis models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Approach 1: Commodity flow approach
    • 1.8.3. Parent Market Analysis (Model 2)
    • 1.8.4. Approach 2: Parent Market Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological advancements & growing R&D investments
      • 3.2.1.2. Rising demand for topical medications
      • 3.2.1.3. Expansion of manufacturing capacities and partnerships
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
  • 3.3. North America Topical Drugs CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
  • 3.4. Pricing Analysis
  • 3.5. Topical Drugs CDMO Capacity Outlook
    • 3.5.1. CDMO Manufacturing Container Capacity
    • 3.5.2. Topical Drugs Container Capacity By Product Type
  • 3.6. North America Topical Drugs CDMO Market Outlook By Product Category
    • 3.6.1. North America Topical Drugs CDMO Market Share, By Product Category, 2023 (%)
    • 3.6.2. Prescription Drugs
      • 3.6.2.1. Segment Overview
      • 3.6.2.2. Major Prescription Drugs, By Product Type
    • 3.6.3. Generic Drugs
      • 3.6.3.1. Segment Overview
      • 3.6.3.2. Major Generic Drugs, By Product Type
    • 3.6.4. Over-the-counter (OTC) Drugs
      • 3.6.4.1. Segment Overview
      • 3.6.4.2. Major OTC Drugs, By Product Type
  • 3.7. Impact of COVID-19 Pandemic

Chapter 4. North America Topical Drugs CDMO Market: Product Type Estimates & Trend Analysis

  • 4.1. Product Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. North America Topical Drugs CDMO Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Semi-solid Formulations
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Creams
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ointments
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lotions
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Liquid Formulations
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Suspensions
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Solutions
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Solid Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Transdermal Products
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America Topical Drugs CDMO Market: Service Type Estimates & Trend Analysis

  • 5.1. Service Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. North America Topical Drugs CDMO Market by Service Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Contract Development
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Formulation Development
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Analytical Testing
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Stability Testing
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Contract Manufacturing
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Clinical
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Commercial
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America Topical Drugs CDMO Market: Sponsors Estimates & Trend Analysis

  • 6.1. Sponsors Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. North America Topical Drugs CDMO Market by Sponsors Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Pharmaceutical Companies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Biopharmaceutical Companies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. North America Topical Drugs CDMO Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2023 & 2030
  • 7.2. Country Market Dashboard
  • 7.3. Country Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Regulatory framework
    • 7.5.3. Competitive scenario
    • 7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Canada
    • 7.6.1. Key country dynamics
    • 7.6.2. Regulatory framework
    • 7.6.3. Competitive scenario
    • 7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. The Lubrizol Corporation
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product/service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Cambrex Corporation
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product/service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Contract Pharmaceuticals Limited
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product/service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bora Pharmaceutical CDMO
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product/service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Ascendia Pharmaceuticals
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product/service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pierre Fabre S.A.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product/service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Piramal Pharma Solutions
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product/service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. DPT Laboratories, LTD.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product/service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. MedPharm Ltd.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product/service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Zenvisionpharma
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product/service benchmarking
      • 8.2.10.4. Strategic initiatives